A Phase 2 Open-Label Study in Patients With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant to Explore the Safety And Efficacy of Simeprevir and Sofosbuvir With and Without Ribavirin

Trial Profile

A Phase 2 Open-Label Study in Patients With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant to Explore the Safety And Efficacy of Simeprevir and Sofosbuvir With and Without Ribavirin

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2016

At a glance

  • Drugs Simeprevir (Primary) ; Ribavirin; Sofosbuvir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms GALAXY
  • Sponsors Janssen
  • Most Recent Events

    • 17 Apr 2016 Results of final analysis for 12 weeks presented at The International Liver Congress™ 2016.
    • 11 Apr 2016 Data will be presented at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL), according to a Medivir AB media release.
    • 22 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top